Explore

Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Lead Cancer Drug Development

Byondis Appoints Christoph Korpus as CEO to Lead Cancer Drug Development

Byondis Appoints Christoph Korpus as CEO to Lead Cancer Drug Development
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Lead Biopharmaceutical Innovations

Byondis Appoints Christoph Korpus as CEO to Lead Biopharmaceutical Innovations

Byondis Appoints Christoph Korpus as CEO to Lead Biopharmaceutical Innovations
Trendline Trendline
Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates
Trendline Trendline
Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Orano Appoints Frederic Desdouits as CEO of Orano Med to Drive Oncology Innovations

Orano Appoints Frederic Desdouits as CEO of Orano Med to Drive Oncology Innovations

Orano Appoints Frederic Desdouits as CEO of Orano Med to Drive Oncology Innovations
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology
Trendline Trendline
Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment
Trendline Trendline
CenExel Appoints Dr. Sy Pretorius as CEO to Drive Strategic Growth

CenExel Appoints Dr. Sy Pretorius as CEO to Drive Strategic Growth

CenExel Appoints Dr. Sy Pretorius as CEO to Drive Strategic Growth